Skip to content

Alumis Inc. ALMS Enterprise value

Enterprise value at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$158.92B-2.6%
Amgen logo
AmgenAMGN
$246.43B+9.9%
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$2.38B+690%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
$2.08B+74.4%
Vera Therapeutics logo
Vera TherapeuticsVERA
$2.83B+85.0%
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
$3.82B+565%

Other financials

Income statement

See full
Revenue$1.7M-90.0%
Operating income-$98.4M+3.1%
Net income-$93.1M+6.0%
EPS (diluted)-$0.74+59.3%

Balance sheet

See full
Cash & equivalents$63.9M-50.3%
Total debt$35.7M+1,881%
Total equity$567.0M+237%
Total assets$671.6M+157%

Cash flow

See full
Operating cash flow-$87.1M-8.4%
CapEx$164.0K+343%
Free cash flow-$87.2M-8.5%

Valuation

See full
Market cap$3.12B+739%
P/S371.9×

Profitability

See full
Operating margin-5,364%
Net margin-2,825.7%
FCF margin-4,487.4%

Returns & leverage

See full
Return on equity-64.6%
Debt / equity0.1×+0.1×
Current ratio7.5×+3.8×

Where this comes from

Calculated from Alumis Inc.’s reported figures.

The official record: Alumis Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alumis Inc.'s enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alumis Inc.'s enterprise value?
Alumis Inc. (ALMS) reported enterprise value of $2.77B in Q1 2026.
How has Alumis Inc.'s enterprise value changed year-over-year?
Alumis Inc.'s enterprise value increased by 1238.0% year-over-year, from $207.32M to $2.77B.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.